No Significant Benefit with Rosiglitazone in Preventing Progression of Atherosclerosis in Diabetic Patients with a History of Cardiovascular Disease

Summary

Thiazolidinediones, such as rosiglitazone, have been shown to increase insulin sensitivity and reduce other cardiovascular risk factors but increase fluid retention and the risk of heart failure. This article discusses results of the Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History [APPROACH; NCT00116831] trial.

  • diabetes mellitus
  • lipid disorders
  • prevention & screening clinical trials
  • prevention & screening
View Full Text